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We assessed structural elements of the retina in individuals with Friedreich ataxia (FRDA) and in mouse
models of FRDA, as well as functions of the retinal pigment epithelium (RPE) in FRDA using induced
pluripotent stem cells (iPSCs). We analyzed the retina of the FRDA mouse models YG22R and YG8R
containing a human FRATAXIN (FXN) transgene by histology. We complemented this work with post-
mortem evaluation of eyes from FRDA patients. Finally, we derived RPE cells from patient FRDA-iPSCs to
assess oxidative phosphorylation (OXPHOS) and phagocytosis. We showed that whilst the YG22R and
YG8R mouse models display elements of retinal degeneration, they do not recapitulate the loss of retinal
ganglion cells (RGCs) found in the human disease. Further, RPE cells differentiated from human FRDA-
iPSCs showed normal OXPHOS and we did not observe functional impairment of the RPE in Humans.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Friedreich ataxia (FRDA) is a hereditary degenerative disease that
presents with both neuronal and non-neuronal manifestations in-
cluding ataxia, dysarthria, cardiomyopathy, diabetes mellitus, and
impairment of auditory and visual functions [1]. Cardiomyopathy is
the leading cause of death in FRDA and usually presents as a hyper-
trophy, which can commonly progress to dilated cardiomyopathy and
arrhythmias [1]. The defective gene FRATAXIN (FXN) has been identi-
ﬁed in the majority of affected individuals, as containing an unstable
GAA repeat mutation within the ﬁrst intron [2]. FXN is a nuclear-
encoded mitochondrial protein involved in iron–sulfur cluster as-
sembly, heme synthesis, and intracellular iron homeostasis [1]. The
levels of FXN are reduced in individuals with FRDA, as a consequenceB.V. This is an open access article u
lia. 1/32 Gisborne Street, East
9.
).of its reduced transcription due to interference caused by the ex-
panded GAA repeats [1].
In FRDA, ophthalmic manifestations including optic neuropathy
and retinitis pigmentosa-like syndrome have been described in some
patients, suggesting that retinal ganglion cells (RGCs), photoreceptors
and the retinal pigment epithelium (RPE) may be affected [3–5]. Most
data have implicated degeneration of the optic nerve [5–8] but very
little is known of the RPE layer. The RPE plays a major role in the
health of the retina. Photoreceptor death can be associated with RPE
impairment, as this layer plays a supportive role to the photo-
receptors. Further, the RPE accumulates iron, which increases with
aging and has been implicated in retinal degeneration [9–11] and
linked to impairment of RPE functions such as phagocytosis [12].
Given the central role of iron in the pathogenesis of FRDA, we ques-
tioned if the RPE could also be an affected tissue in FRDA.
The difﬁculty in obtaining human tissue and the paucity of
functional assays speciﬁc to RPE function renders the study of the
RPE layer in Humans challenging. A potential way to study RPEnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Assessment of stability of expression of housekeeping genes in PSC-derived RPE
cells.
Targets RPE 1 RPE 2 RPE 3
18s 13.96 13.98 11.96
GAPDH 20.98 21.97 20.99
HPRT1 28.96 28.95 27.95
GUSB 27.98 27.96 27.97
ACTB 21.98 21.98 21.00
B2M 23.95 23.95 22.95
RPLP0 23.95 23.95 22.94
HMBS 29.94 29.94 29.95
TBP 30.94 29.94 29.95
PGK1 23.93 24.93 22.94
UBC 23.95 24.94 23.94
PPIA 22.96 23.96 22.96
qRT-PCR were performed using three different PSC-derived RPE cells from three
independent experiments. Data are shown as raw Ct values. ACTB (bold) was
chosen as the reference housekeeping gene.
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pluripotent stem cells (iPSCs). iPSCs have previously been derived
from individuals with FRDA [13–16], showing that the iPSCs model
intergenerational repeat expansion/contraction [14], and suggest-
ing mitochondrial abnormalities in the iPSC-derived-cardiomyo-
cytes [13,16]. We previously reported the generation of two FRDA-
iPSC lines, FA3 and FA4, which were respectively derived from
individuals with 527/1058 and 751/1027 GAA repeats and showed
instability in repeat numbers in culture [15]. So far, there has been
no study of RPE cells from FRDA-iPSCs.
Another way to determine whether the RPE is involved in FRDA
is by using animal models of the disease. The double mutant
Fxntm1MknTg(FXN)YG22Pook/J mice (YG22R), which carry a Fxn
knock-out and a human FXN transgene, exhibit progressive retinal
degeneration but the pathophysiology of this abnormality has not
been fully characterised (https://www.jax.org/strain/010963).
Using these mice and comparing them to other double mutants
and controls could provide information on the pathophysiology of
retinal degeneration in FRDA. In this study, we used the YG22R
mice, the Fxntm1MknTg(FXN)YG8Pook/J (YG8R) and the Fxntm1Mkn Tg
(FXN)Y47Pook/J (Y47R) mice. The YG8R and the YG22R are
homozygous for the Fxntm1Mkn (Fxn) targeted allele and hemi-
zygous for the human FXN transgene, each with a pure GAA ex-
pansion in the ﬁrst intron [17–20]. These mice differ in the GAA
expansion repeats, with the YG22R having 190 GAA repeats and
the YG8R having 90 and 190 GAA repeats. The Y47R control mice
contain a normal GAA repeat length (9 repeats). A recent analysis
of the YG22R, YG8R and Y47R mice show reduced levels of human
FXN protein to 60% in the YG22R and to 76% in the YG8R in
comparison to the levels observed in the control Y47R in the brain
with some gender variability [21]. Little is known on the impact
the genetic mutations in these models have on the RPE.
Here we used three approaches: mouse models, human post
mortem eyes and iPSC-derived RPE cells-to gain a better picture on
the health of the RPE in FRDA and to determine if any obvious
defects could be modeled in vitro.2. Material and methods
2.1. Ethics
All experimental work performed in this study was approved
by the Human Research Ethics committees of the Eye and Ear
Hospital (09/921H, 11/1031H, 12/1091H) and the University of
Melbourne (0605017, 0829937) and the UK Home Ofﬁce animal
licence PPL30/3031, and completed in accordance with the re-
quirements of the National Health & Medical Research Council of
Australia and the Declaration of Helsinki. This research also ad-
heres to the ARVO statement for the use of animals in ophthalmic
and vision research. For retrieval of human tissue, autopsies and
eye removal were performed after a legally responsible family
member gave formal permission. The Institutional Review Board of
Veterans Affairs Medical Center in Albany, New York, USA, ap-
proved the collection of the autopsy samples for research, their
processing and distribution to researchers, and the posthumous
collection of clinical data.
2.2. Mouse tissue collection and processing
The following mouse models of FRDA were used:
Fxntm1MknTg(FXN)YG8Pook/J mouse (YG8R), the Fxntm1Mkn
Tg(FXN)YG22Pook/J mouse (YG22R) and the Fxntm1Mkn Tg(FXN)
Y47Pook/J (Y47R) control mice [17–20]. C57BL/6 mice were also
used as background controls. Including background and transgene
controls, 40 age– (1670.18 months, 10 per group, 5 males and5 females) and sex- matched mouse eyes were immersion-ﬁxed
in 4% PFA and processed to parafﬁn.
2.3. Morphometric analysis of mouse retinal sections
Sagittal sections were stained with haematoxylin and eosin
(H&E) and the thicknesses of various retinal layers and RPE were
measured using Image J (Image J v1.46r, NIH, USA). Cell counts
were also performed on the RGC layer. All analysis was performed
blinded to the identity of the sections. Four measurements from
four equivalent regions across each retina were obtained in tri-
plicate serial sections for each animal. For analysis, measurements
were normalized to the thickness of the entire retina (INL-ONL)
except for the inner retina layers which were normalized across
the inner retina, to account for obliquely cut sections.
2.4. Collection of human eyes
Six human eyes from individuals with FRDA were collected
during autopsy, together with other tissues, and were de-identi-
ﬁed before delivery to the researchers. Brieﬂy, eyes were removed
either through enucleation or through the orbital roof after re-
moval of the brain. They were then ﬁxed by immersion in for-
malin. After 1 h, a frontal cut was performed through the eyes to
allow formalin to reach the retina.
2.5. Pathology of post-mortem FRDA eyes
The six ﬁxed post-mortem eyes from FRDA patients were hand
processed through graded alcohols and xylene to parafﬁn. Sagittal
sections were cut at 7 mm and stained with H&E. transversely
sectioned at 5 mm and stained with haematoxylin and eosin and
Luxol fat blue. The sixth eye had no retrobulbar optic nerve,
so optic atrophy was assessed from the intrabulbar portion. All
sections were assessed for abnormalities in RPE, retina, optic disc
and nerve by a pathologist.
2.6. Cell culture
The FRDA iPSC lines FA3 and FA4 [15] and the hESC line H9 [22]
were maintained as described in [15]. PSCs were differentiated
into RPE cells according to [23]. After 30–60 days, pigmented cells
were manually isolated and transferred to organ culture dishes in
15% fetal bovine serum (FBS) medium containing taurine, hydro-
cortisone and triiodothyronine (15% RPE medium) [23]. After 24 h
the medium was replaced with RPE medium containing 5% FBS
Fig. 1. Histomorphometric analysis of mouse retinas. Measurement in female (F) and male (M) mice of the IPL (A), INL (B), OPL (C), ONL (D), PIS/POS (E–F) in C57BL/6 (B6),
Y47R, YG8R and YG22R mice. Analysis of RPE (G) and RGC count (H) demonstrated no signiﬁcant differences between sex so these data were combined for assessment. Data
is expressed as mean7SEM relative thickness (A–F), thickness (G) or cell number (H). (A–H) Statistics 2-way ANOVA with Bonferroni’s multiple comparison test. *po0.05
**po0.01, ****po0.0001. n¼10 mice per group (5 males, 5 females); 4 measurements from 4 equivalent regions across each retina were obtained in triplicate serial sections
for each animal. (I–L) Representative images of sections used for analysis in C57BL/6 (I), Y47R (J), YG8R (K) and YG22R (L) mice. Scale bar: 50 mm.
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Fig. 2. Histochemistry staining of FRDA human eyes. H&E stained retinal (left
column, 20 objective) and optic nerve sections (right column, 4 objective)
from FRDA post-mortem tissues from sample 1 (A, B) a FRDA patient with normal
optic nerve and retina; 2 (C, D), 3 (E, F), 4 (G, H), 5 (I, J) and 6 (K), demonstrating
varying degrees of optic nerve atrophy and cell loss from the RGC layer (arrows).
Extra-bulbar optic nerve from sample 6 was not available for analysis. Scale bars:
100 μm for retinal sections, 500 μm for optic nerve sections.
D.E. Crombie et al. / Biochemistry and Biophysics Reports 4 (2015) 141–147144(5% RPE medium) [23]. Conﬂuent RPE cells were subsequently
passaged up to three times with 0.25% Trypsin–EDTA at a density
of 50,000–100,000 cells per cm2 in 15% RPE medium. Onceattached, RPE cells were switched to 5% RPE medium and ex-
panded until conﬂuence, re-pigmentation and mature polygonal
morphology were observed. RPE cells were used for assays
between passage 1–3 post manual isolation.
2.7. qPCR for markers of RPE cells and FXN expression
RNA extraction and cDNA synthesis was performed using the
RNeasy Minikit (Qiagen) and the High-Capacity cDNA reverse tran-
scription kit (Invitrogen) as per manufacturers instruction. qPCR was
performed on a 7900HT Fast Realtime PCR system (Applied Biosys-
tems) with 2ng of cDNA per reaction, using the following
primers: GAPDH (Hs 99999905_m1), HPRT1 (Hs99999909_m1),
GUSB (Hs99999908_m1), beta-ACTIN (ACTB, Hs99999903_m1),
B2M (Hs99999907_m1), RPLP0 (Hs99999902_m1), HMBS
(Hs00609297_m1), TBP (Hs99999910_m1), PGK1 (Hs99999906_m1),
UBC (Hs00824723_m1), PPIA (Hs99999904_m1), PAX6
(Hs00240871_m1), SIX3 (Hs00193667_m1), RAX (Hs00429459_m1),
MITF (Hs01117294_m1), PMEL (Hs00173854_m1), RLBP1
(Hs00165632_m1), RPE65 (Hs01071462_m1) and FXN
(Hs00175940_m1). Housekeeping genes were assessed for their
stability of expression in three independent cultures of PSC-derived
RPE cells (Table 1). Subsequently, ACTB was selected as the house-
keeping gene. Data is expressed as mean7SEM relative gene
expression using the delta-delta CT method for each gene assay
measured.
2.8. High resolution respirometry
Maximal mitochondrial respiration was measured by providing
artiﬁcially high levels of complex-I and –II substrates in the pre-
sence of excess ADP to maximize coupled mitochondrial respiration
rates, as described in [24]. Mitochondrial respiration was uncoupled
from the inhibitory feedback loop on OXPHOS provided by ATP
synthase with addition of the uncoupler carbonyl cyanide m-
chlorophenyl hydrazone (CCCP). Residual oxygen consumption was
measured by adding rotenone and antimycin A. Brieﬂy, 24 h prior to
experiment, RPE medium was changed. 1.5106 RPE cells har-
vested by trypsinisation for 10 min were re-suspended in respira-
tion buffer (200 mM sucrose, 20 mM taurine, 20 mM HEPES, 10 mM
KH2PO4, 3 mM MgCl2, 3 mM EGTA, 1 g/L fatty acid free BSA; pH 7.1)
as described [25] and added to each chamber. Following equili-
bration with ambient oxygen for at least 10 min with stirring, the
chamber was closed. Glutamate (10 mM) and malate (2 mM)
were added, followed by the optimized digitonin concentration
(10 μg/mL) for each cell line. ADP (1 mM), succinate (10 mM), CCCP
(1.5 μM), rotenone (5 μM) and antimycin A (2 μM) were added at
intervals of approximately 2 min. Respiration states measured in-
cluded endogenous respiration rate (with endogenous substrates),
ADP-stimulated cell respiration with glutamateþmalate (CxI-ADP)
or with succinate (CxIþ II-ADP) and the uncoupled maximal re-
spiration (UC) by the addition of CCCP. On average the residual
oxygen consumption (ROX; when rotenone and antimycin A in-
hibited mitochondrial respiration) was less than 1% of the UC rate.
2.9. Photoreceptor outer segments (POS) isolation and labeling
POS were isolated according to established protocols [26,27]
from 40 bovine eyes fresh from the slaughterhouse. POS were
incubated with 0.4 mg/mL Fluorescein isothyocyanate (FITC) iso-
mer (Life Technologies) for 1.5 h at room temperature with gentle
rotation. FITC-labeled POS (FITC-POS) were washed twice in 10%
sucrose, 20 mM sodium phosphate pH 7.2, 5 mM taurine, then
once in DMEM, and resuspended in DMEM with 2.5% sucrose,
counted, aliquoted and stored at 80 C.
Table 2
FRDA post-mortem eye pathology








Cause of death (heart
weight)
Pathology
1 M 10 24 14 1050/700 Cardiomyopathy (565) Mild concavity of the optic disc - some artefactual proces-
sing issues - essentially normal optic nerve and retina
2 F 15 69 54 560/560 Cardiomyopathy (359) Some retinal ganglion cell loss and optic nerve atrophy -
previous extracapsular cataract extraction and IOL, partial
angle closure
3 M 4 37 33 850/850 Cachexia (419) Severe retinal ganglion cell loss and optic nerve atrophy
4 M 9 33 24 925/925 Cardiomyopathy (421) Mild to moderate retinal ganglion cell loss
5 F 7 28 21 681/837 Cachexia (362) Retinal ganglion cell loss and optic nerve atrophy
6 F 5 25 20 734/734 Cardiomyopathy (325) Moderate to severe retinal ganglion cell loss and optic
nerve atrophy
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Phagocytosis was assessed by ﬂow cytometry [28]. Freshly
thawed FITC-POS were diluted into CO2-independent medium
(Life Technologies) and incubated with RPE cells (375,000 FITC-
POS per cm2) for 4 h at 37 °C. Cells were harvested with 0.25%
Trypsin–EDTA, incubated with 5 mM DRAQ5 as a viability dye in
RPE medium, passed through a 0.45 mm cell strainer, then ana-
lyzed on a Becton Dickinson FACS Aria III ﬂow cytometer. Data
analysis was performed using FCS Express 5 (DeNovo Software).
The percentage of RPE cells that internalized FITC-POS was mea-
sured from the DRAQ5-positive live cell population.
2.11. Statistical analysis
All statistical analyses and graphical data were generated using
Graphpad Prism software (v6.02, www.graphpad.com). Statistical
methods utilized were one-way and two-way ANOVA followed
Bonferroni’s multiple comparisons test. Data are presented as
mean7SEM. Statistical signiﬁcance was established as po0.05,
**po0.01, ***po0.001, ****po0.0001.3. Results
3.1. FRDA-mouse retina analysis
Measurements of the inner plexiform layer (IPL), inner nuclear
layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL),
photoreceptor inner/outer segments (PIS/POS) and RPE layer thick-
ness, as well as cell count of the RGCs on retinal sections from FRDA
mutant mice and control mice were performed (Fig. 1). No signiﬁcant
difference in the IPL or INL was observed between the groups of mice
(Fig. 1(A–B)) when corrected to the total IPLþ INL thickness. A trend
in reductions of the INL and POS was observed in the YG8Rmales but
this was not statistically signiﬁcant (Fig. 1(A–F)). Both male and fe-
male YG22R mice displayed a signiﬁcant loss of the OPL and ONL
(Fig. 1(C–D)) and a signiﬁcant reduction in length of PIS and POS
(Fig. 1(E–F)). Analysis of the RPE layer demonstrated no signiﬁcant
differences between males and females or region so these data were
combined for assessment (Fig. 1(G–H)). Compared to the C57BL/6
background controls, YG8R and YG22R showed a signiﬁcant thinning
of the RPE layer but the thickness was not statistically different to the
one measured in the Y47R transgene control mice (Fig. 1(G)). Lastly,
cell count did not reveal signiﬁcant modiﬁcations in RGC layer
numbers in any group.
3.2. FRDA-post mortem eye pathology
Because of the supportive role of the RPE to photoreceptors,
and given the retinal degeneration of the ONL and OPL in themouse, we assessed the RPE layers in Humans. Also, because we
did not observe variation in cell numbers of the RGC layer in the
YG22R mice compared to control mice, we examined the optic
nerve in Humans. Histological assessment of the six FRDA-post
mortem eyes revealed variable degrees of loss of RGCs, thinning of
the retinal nerve ﬁber layer and optic nerve atrophy (Fig. 2). The
severity of optic nerve atrophy and RGC loss correlated with age of
onset (Table 2), as has been previously reported [4]. No apparent
abnormalities in the RPE were noted in the post-mortem eyes.
3.3. FRDA-iPSC-derived RPE cell analysis
To further assess a potential FRDA phenotype in the human
RPE, we derived RPE cells from the FRDA-iPSCs FA3 and FA4.
These cells show pigmentation and the typical cobblestone mor-
phology, express markers of RPE cells and reduced levels of FXN
(Fig. 3(A–C)). RPE cells were analyzed for their OXPHOS activity, in
an Oxygraph 2 K high resolution respirometer with a protocol
optimized for analyzing activity of Complex I and Complex II. We
observed no statistical difference in FA3- and FA4-RPE cells when
compared to control RPE cells (Fig. 3(D and E)). Flow cytometry
analysis of phagocytosis by the FRDA-RPE cells showed that
greater than 95% of FA3- and FA4-derived RPE cells were capable
of phagocytosis (Fig. 3(F–H)). Altogether, this data demonstrates
that despite low level of FXN, these cells remain functional.4. Discussion
Our study demonstrated elements of outer retina degeneration
with photoreceptor loss in the YG22R mouse model of FRDA. We
also observed a signiﬁcant thinning of the RPE layer in YG8R and
YG22R when compared with the background control mice, but this
was not observed when compared to the Y47R transgene control
mice. This suggests an effect of transgene insertion rather than
FXN deﬁciency. We did not observe variation in cell numbers in
the ganglion cell layer, in both YG8R and YG22R. The cell count
performed within this layer of the retina also accounts for dis-
placed amacrine cells [29]. Although a variation in the balance of
cell types is possible, it is unlikely, given that others showed that
most neuronal changes in the aging retina is of RGCs and not in-
terneurons such as the amacrine cells [30]. Thus our data suggest
no RGC death in the two mouse models of FRDA. We did not
measure the optic nerve thickness in these animals because of
technical limitations in the harvesting of the mouse eyes. Yet, optic
nerve degeneration can precede RGC soma loss [31,32] and we
cannot exclude this possibility in these animals.
Fxn is expressed in the retina of normal mice, especially in the
photoreceptors and also in the RGCs [33]. Eﬁmova and Trottier
described that in R7E mice that present with retinal degeneration,
the fxn expression pattern is modiﬁed and increases as
Fig. 3. Analysis of iPSC-derived RPE cells. (A) FRDA-iPSC-derived-RPE showing typical cobblestone morphology and pigmentation. (B) mRNA expression of RPE markers
PMEL17, SIX3,MITF, PAX6, RAX, RLBP1 and RPE65 in H9-derived- (control), FA3-derived- and FA4-derived- RPE cells relative to undifferentiated cells; (C) FXNmRNA expression
relative to H9-derived RPE cells. Data expressed as mean7SEM relative gene expression using the delta-delta CT method for each gene assay measured. (D, E) High
resolution respirometry. Respiration is shown as mean oxygen ﬂow per million cells of endogenous unstimulated respiration (Endo), ADP stimulated complex I activity (CXI-
ADP), ADP stimulated complex Iþ II activity (CXIþ II-ADP), Maximal uncoupled respiration (UC), Maximal uncoupled respiration following complex I inhibition with Ro-
tenone (ROT). The data normalized to UC is displayed as percentage of the UC rate. (B–E) Statistics were performed using 1-way ANOVA (B), 2-way ANOVA with Bonferroni’s
multiple comparison test (C, D, E), nZ3 independent experiments. ***po0.001. (F–H) Flow cytometry analysis of phagocytosis by control- (F), FA3- (G) and FA4- (H) RPE cells
showing phagocytosis after incubation with FITC-POS (37 °C); controls: untreated cells.
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in fxn expression might be used by photoreceptors as a protection
mechanism against apoptosis, through the anti-oxidant role of fxn
[33]. In this present study, we do not know the exact amount of
human FXN expressed in the mouse retina. However, we can as-
sume that human FXN levels are lower in the retina of the YG22R
and YG8R compared to the control Y47R, as the levels of FXN in the
brain were found to be lower in YG22R and YG8R mice compared
to Y47R [21]. Although the retinal degeneration observed in YG22R
is likely to be an effect of transgene insertion rather than FXN
deﬁciency (as there was no statistical difference observed with itscontrol Y47R), it remains possible that the retinal degeneration
observed in the YG22R mimics the phenotype observed in the R7E
as the low levels of FXN do not have sufﬁcient anti-oxidant cap-
abilities to protect photoreceptors from death. This however, is not
a feature of the human FRDA pathology.
Using human FRDA eyes, we observed that one sample was
largely regarded as normal, whilst others showed optic nerve
atrophy and RGC loss, in accordance with reports from the litera-
ture [34,35]. Additionally there were no obvious morphological
signs of RPE pathology in the human eyes, suggesting that if af-
fected, the changes in these cell types could be subclinical and not
D.E. Crombie et al. / Biochemistry and Biophysics Reports 4 (2015) 141–147 147critical to disease pathogenesis. To the best of our knowledge, this
study is the ﬁrst to present histology of post-mortem human FRDA
eyes.
Further experimentation of OXPHOS in RPE cells derived from
FRDA-iPSCs demonstrated no signiﬁcant changes in OXPHOS ac-
tivity and normal phagocytosis in the FRDA-derived RPE cells.
Altogether our data suggest that the RPE layer pathology is not a
signiﬁcant feature in FRDA visual dysfunction.Grant information
This work was supported by an Australian Research Council
Future Fellowship (FT140100047, AP), a NHMRC Career Develop-
ment Fellowship (AP), a NHMRC-CSL Gustav Nossal postgraduate
research scholarship (DEC), a NHMRC Early Career Fellowship
(LAC), a Gerard Crock Fellowship (KCD), a National Stem Cell
Foundation of Australia grant and an Ophthalmic Research In-
stitute of Australia/RANZCO Eye Foundation Grant. CERA receives
Operational Infrastructure Support from the Victorian
Government.Acknowledgments
The authors wish to thank Dr AH Koeppen (VA Medical Center,
Albany, New York, USA) for providing the autopsy samples of
Friedreich ataxia eyes on behalf of FARA-USA.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.bbrep.2015.09.
003.References
[1] M.V. Evans-Galea, A. Pebay, M. Dottori, L.A. Corben, S.H. Ong, P.J. Lockhart, M.
B. Delatycki, Cell and gene therapy for Friedreich ataxia: progress to date,
Hum. Gene Ther. 25 (2014) 684–693.
[2] V. Campuzano, L. Montermini, M.D. Molto, L. Pianese, M. Cossee, F. Cavalcanti,
E. Monros, F. Rodius, F. Duclos, A. Monticelli, F. Zara, J. Canizares,
H. Koutnikova, S.I. Bidichandani, C. Gellera, A. Brice, P. Trouillas, G. De Michele,
A. Filla, R. De Frutos, F. Palau, P.I. Patel, S. Di Donato, J.L. Mandel, S. Cocozza,
M. Koenig, M. Pandolfo, Friedreich’s ataxia: autosomal recessive disease
caused by an intronic GAA triplet repeat expansion, Science 271 (1996)
1423–1427.
[3] C.D. Alldredge, C.R. Schlieve, N.R. Miller, L.A. Levin, Pathophysiology of the
optic neuropathy associated with Friedreich ataxia, Arch. Ophthalmol. 121
(2003) 1582–1585.
[4] F. Fortuna, P. Barboni, R. Liguori, M.L. Valentino, G. Savini, C. Gellera,
C. Mariotti, G. Rizzo, C. Tonon, D. Manners, R. Lodi, A.A. Sadun, V. Carelli, Visual
system involvement in patients with Friedreich’s ataxia, Brain 132 (2009)
116–123.
[5] S. Noval, I. Contreras, I. Sanz-Gallego, R.K. Manrique, J. Arpa, Ophthalmic fea-
tures of Friedreich ataxia, Eye 26 (2012) 315–320.
[6] L.A. Seyer, K. Galetta, J. Wilson, R. Sakai, S. Perlman, K. Mathews, G.R. Wilmot,
C.M. Gomez, B. Ravina, T. Zesiewicz, K.O. Bushara, S.H. Subramony,
T. Ashizawa, M.B. Delatycki, A. Brocht, L.J. Balcer, D.R. Lynch, Analysis of the
visual system in Friedreich ataxia, J. Neurol. 260 (2013) 2362–2369.
[7] E. Dag, N. Ornek, K. Ornek, I.E. Erbahceci-Timur, Optical coherence tomography
and visual ﬁeld ﬁndings in patients with Friedreich ataxia, J. Neuroophthalmol.
34 (2014) 118–121.
[8] B. Diehl, M.S. Lee, J.R. Reid, C.D. Nielsen, M.R. Natowicz, Atypical, perhaps
under-recognized? An unusual phenotype of Friedreich ataxia, Neurogenetics
11 (2010) 261–265.
[9] X. He, P. Hahn, J. Iacovelli, R. Wong, C. King, R. Bhisitkul, M. Massaro-Giordano,
J.L. Dunaief, Iron homeostasis and toxicity in retinal degeneration, Prog. Retin.
Eye Res. 26 (2007) 649–673.
[10] R.W. Wong, D.C. Richa, P. Hahn, W.R. Green, J.L. Dunaief, Iron toxicity as a
potential factor in AMD, Retina 27 (2007) 997–1003.[11] D. Song, J.L. Dunaief, Retinal iron homeostasis in health and disease, Front.
Aging Neurosci. 5 (2013) 24.
[12] H. Chen, T.J. Lukas, N. Du, G. Suyeoka, A.H. Neufeld, Dysfunction of the retinal
pigment epithelium with age: increased iron decreases phagocytosis and ly-
sosomal activity, Invest. Ophthalmol. Vis. Sci. 50 (2009) 1895–1902.
[13] A. Hick, M. Wattenhofer-Donzé, S. Chintawar, P. Tropel, J.P. Simard,
N. Vaucamps, D. Gall, L. Lambot, C. André, L. Reutenauer, M. Rai, M. Teletin,
N. Messaddeq, S.N. Schiffmann, S. Viville, C.E. Pearson, M. Pandolfo, H. Puccio,
Neurons and cardiomyocytes derived from induced pluripotent stem cells as a
model for mitochondrial defects in Friedreich’s ataxia, Dis. Models Mech. 6
(2013) 608–621.
[14] S. Ku, E. Soragni, E. Campau, E.A. Thomas, G. Altun, L.C. Laurent, J.F. Loring,
M. Napierala, J.M. Gottesfeld, Friedreich’s ataxia induced pluripotent stem cells
model intergenerational GAATTC triplet repeat instability, Cell Stem Cell 7
(2010) 631–637.
[15] J. Liu, P.J. Verma, M.V. Evans-Galea, M.B. Delatycki, A. Michalska, J. Leung,
D. Crombie, J.P. Sarsero, R. Williamson, M. Dottori, A. Pebay, Generation of
induced pluripotent stem cell lines from Friedreich ataxia patients, Stem Cell
Rev. 7 (2011) 703–713.
[16] Y.K. Lee, P.W. Ho, R. Schick, Y.M. Lau, W.H. Lai, T. Zhou, Y. Li, K.M. Ng, S.L. Ho, M.
A. Esteban, O. Binah, H.F. Tse, C.W. Siu, Modeling of Friedreich ataxia-related
iron overloading cardiomyopathy using patient-speciﬁc-induced pluripotent
stem cells, Pﬂugers Arch. 466 (2014) 1831–1844.
[17] M.A. Pook, S. Al-Mahdawi, C.J. Carroll, M. Cossee, H. Puccio, L. Lawrence,
P. Clark, M.B. Lowrie, J.L. Bradley, J.M. Cooper, M. Koenig, S. Chamberlain,
Rescue of the Friedreich’s ataxia knockout mouse by human YAC transgenesis,
Neurogenetics 3 (2001) 185–193.
[18] S. Al-Mahdawi, R.M. Pinto, D. Varshney, L. Lawrence, M.B. Lowrie, S. Hughes,
Z. Webster, J. Blake, J.M. Cooper, R. King, M.A. Pook, GAA repeat expansion
mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to
progressive neuronal and cardiac pathology, Genomics 88 (2006) 580–590.
[19] S. Al-Mahdawi, R.M. Pinto, P. Ruddle, C. Carroll, Z. Webster, M. Pook, GAA
repeat instability in Friedreich ataxia YAC transgenic mice, Genomics 84
(2004) 301–310.
[20] S. Al-Mahdawi, R.M. Pinto, O. Ismail, D. Varshney, S. Lymperi, C. Sandi,
D. Trabzuni, M. Pook, The Friedreich ataxia GAA repeat expansion mutation
induces comparable epigenetic changes in human and transgenic mouse brain
and heart tissues, Hum. Mol. Genet. 17 (2008) 735–746.
[21] S. Anjomani Virmouni, C. Sandi, S. Al-Mahdawi, M.A. Pook, Cellular, molecular
and functional characterisation of yac transgenic mouse models of friedreich
ataxia, PLoS One 9 (2014) e107416.
[22] J.A. Thomson, J. Itskovitz-Eldor, S.S. Shapiro, M.A. Waknitz, J.J. Swiergiel, V.
S. Marshall, J.M. Jones, Embryonic stem cell lines derived from human blas-
tocysts, Science 282 (1998) 1145–1147.
[23] A. Maminishkis, S. Chen, S. Jalickee, T. Banzon, G. Shi, F.E. Wang, T. Ehalt, J.
A. Hammer, S.S. Miller, Conﬂuent monolayers of cultured human fetal retinal
pigment epithelium exhibit morphology and physiology of native tissue, In-
vest. Ophthalmol. Vis. Sci. 47 (2006) 3612–3624.
[24] N.J. Van Bergen, R.E. Blake, J.G. Crowston, I.A. Trounce, Oxidative phosphor-
ylation measurement in cell lines and tissues, Mitochondrion 15 (2014) 24–33.
[25] S. Stadlmann, G. Rieger, A. Amberger, A.V. Kuznetsov, R. Margreiter, E. Gnaiger,
H2O2-mediated oxidative stress versus cold ischemia-reperfusion: mitochon-
drial respiratory defects in cultured human endothelial cells, Transplantation
74 (2002) 1800–1803.
[26] R.S. Molday, D. Hicks, L. Molday, Peripherin. A rim-speciﬁc membrane protein
of rod outer segment discs, Invest. Ophthalmol. Vis. Sci. 28 (1987) 50–61.
[27] R. Singh, M.J. Phillips, D. Kuai, J. Meyer, J.M. Martin, M.A. Smith, E.T. Perez,
W. Shen, K.A. Wallace, E.E. Capowski, L.S. Wright, D.M. Gamm, Functional
analysis of serially expanded human iPS cell-derived RPE cultures, Invest.
Ophthalmol. Vis. Sci. 54 (2013) 6767–6778.
[28] P.D. Westenskow, S.K. Moreno, T.U. Krohne, T. Kurihara, S. Zhu, Z.N. Zhang,
T. Zhao, Y. Xu, S. Ding, M. Friedlander, Using ﬂow cytometry to compare the
dynamics of photoreceptor outer segment phagocytosis in iPS-derived RPE
cells, Invest. Ophthalmol. Vis. Sci. 53 (2012) 6282–6290.
[29] C.J. Jeon, E. Strettoi, R.H. Masland, The major cell populations of the mouse
retina, J. Neurosci. 18 (1998) 8936–8946.
[30] M.A. Samuel, Y. Zhang, M. Meister, J.R. Sanes, Age-related alterations in neu-
rons of the mouse retina, J. Neurosci. 31 (2011) 16033–16044.
[31] B.P. Buckingham, D.M. Inman, W. Lambert, E. Oglesby, D.J. Calkins, M.R. Steele,
M.L. Vetter, N. Marsh-Armstrong, P.J. Horner, Progressive ganglion cell de-
generation precedes neuronal loss in a mouse model of glaucoma, J. Neurosci.
28 (2008) 2735–2744.
[32] D.J. Calkins, Age-related changes in the visual pathways: blame it on the axon,
Invest. Ophthalmol. Vis. Sci. 54 (2013) 41 , ORSF37.
[33] M.G. Eﬁmova, Y. Trottier, Distribution of frataxin in eye retina of normal mice
and of transgenic R7E mice with retinal degeneration, J. Evolut. Biochem.
Physiol. 46 (2010) 414–417.
[34] M.H. Parkinson, S. Boesch, W. Nachbauer, C. Mariotti, P. Giunti, Clinical fea-
tures of Friedreich’s ataxia: classical and atypical phenotypes, J. Neurochem.
126 (Suppl 1) (2013) S103–S117.
[35] V. Carelli, C. La Morgia, M.L. Valentino, P. Barboni, F.N. Ross-Cisneros, A.
A. Sadun, Retinal ganglion cell neurodegeneration in mitochondrial inherited
disorders, Biochim. Biophys. Acta 2009 (1787) 518–528.
